View More Recent Stories
-
Plus Therapeutics (PSTV) to Present Positive FORESEE Clinical Trial Summary
-
Plus Therapeutics Inc. (PSTV) PT Lowered to $10 at Jones Trading
-
H.C. Wainwright Reiterates Buy Rating on Plus Therapeutics Inc. (PSTV)
-
Plus Therapeutics (PSTV) Misses Q3 EPS by 37c
-
Plus Therapeutics (PSTV) and SpectronRx Announce Radiotherapeutic Manufacturing Partnership
-
Plus Therapeutics (PSTV) Files $100M Mixed Shelf
-
Plus Therapeutics (PSTV) Reports ReSPECT-GBM Clinical Trial Update
-
Plus Therapeutics (PSTV) Showcases New Interim ReSPECT-GBM Phase 2 Trial Data
-
Plus Therapeutics Inc. (PSTV) PT Lowered to $20 at Ascendiant Capital
-
Plus Therapeutics (PSTV) Misses Q2 EPS by 71c
-
Plus Therapeutics (PSTV) Presents Positive Clinical Trial Results at the 2024 SNO/ASCO CNS Metastases Conference
-
Plus Therapeutics (PSTV) Presents Positive Interim ReSPECT-LM Phase 1 Data for Leptomeningeal Metastases at 2024 SNO/ASCO CNS Metastases Conference
-
Plus Therapeutics (PSTV) Files for 10.77M Share Offering by Selling Stockholders

